Integrated Investment Consultants LLC Has $340,000 Position in Repligen Co. (NASDAQ:RGEN)

Integrated Investment Consultants LLC raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 6.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,360 shares of the biotechnology company’s stock after buying an additional 134 shares during the period. Integrated Investment Consultants LLC’s holdings in Repligen were worth $340,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of RGEN. Champlain Investment Partners LLC boosted its stake in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares during the period. DF Dent & Co. Inc. boosted its stake in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after buying an additional 121,305 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in shares of Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock valued at $18,796,000 after buying an additional 102,100 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $160.51 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $8.99 billion, a PE ratio of -433.80, a price-to-earnings-growth ratio of 4.14 and a beta of 0.97. The company’s fifty day moving average price is $148.36 and its 200 day moving average price is $144.64. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the business posted $0.23 EPS. As a group, analysts expect that Repligen Co. will post 1.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on RGEN shares. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.